Pharmagest Interactive
- Home ›
- FR ›
- Healthcare
Pharmagest Interactive SA engages in the development and commercialization of IT solutions for pharmacies and the pharmaceutical industry in Europe. The last earnings update was 148 days ago. More info.
Add to Portfolio Compare Print Invest
PHA Share Price and Events
PHA Value
Value is all about what a company is worth versus what price it is
available for. If you went into a grocery store and all the bananas were on sale
at half price, they could be considered
undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
Here we compare the current
share
price of
Pharmagest Interactive
to its discounted cash flow analysis.value.The discounted cash flow value is simply looking at what the company is worth today, based on estimates of how much money it is expected to make in the future.
Below are the data sources, inputs and calculation used to determine the intrinsic value for Pharmagest Interactive.
| Data Point | Source | Value |
|---|---|---|
| Valuation Model | 2 Stage Free Cash Flow to Equity | |
| Levered Free Cash Flow | Average of 3 Analyst Estimates (S&P Global) | See below |
| Discount Rate (Cost of Equity) | See below | 8.2% |
| Perpetual Growth Rate | 10-Year FR Government Bond Rate | 0.8% |
An important part of a discounted cash flow is the discount rate, below we explain how it has been calculated.
| Data Point | Calculation/ Source | Result |
|---|---|---|
| Risk-Free Rate | 10-Year FR Govt Bond Rate | 0.8% |
| Equity Risk Premium | S&P Global | 9.2% |
| Healthcare Services Unlevered Beta | Simply Wall St/ S&P Global | 0.56 |
| Re-levered Beta | = Unlevered beta (1 + (1- tax rate) (Debt/Equity))
= 0.559 (1 + (1- 33%) (1.84%)) |
0.565 |
| Levered Beta | Levered Beta limited to 0.8 to 2.0 (practical range for a stable firm) |
0.8 |
| Discount Rate/ Cost of Equity |
= Cost of Equity = Risk Free Rate + (Levered Beta * Equity Risk Premium)
= 0.78% + (0.8 * 9.22%) |
8.16% |
Discounted Cash Flow Calculation for ENXTPA:PHA using 2 Stage Free Cash Flow to Equity Model
The calculations below outline how an intrinsic value for Pharmagest Interactive is arrived at by discounting future cash flows to their present value using the 2 stage method. We use analyst's estimates of cash flows going forward 5 years for the 1st stage, the 2nd stage assumes the company grows at a stable rate into perpetuity.
| 2019 | 2020 | 2021 | 2022 | 2023 | |
| Levered FCF (EUR, Millions) | 29.20 | 38.05 | 40.00 | 42.04 | 44.19 |
| Source | Analyst x2 | Analyst x2 | Est @ 5.11% | Est @ 5.11% | Est @ 5.11% |
|
Present Value Discounted (@ 8.16%) |
27.00 | 32.53 | 31.61 | 30.72 | 29.86 |
| Present value of next 5 years cash flows | €151.72 |
| Calculation | Result | |
|---|---|---|
| Terminal Value |
= FCF2023
× (1 + g) ÷ (Discount Rate – g)
= €44.19 × (1 + 0.78%) ÷ (8.16% – 0.78%) |
€603.64 |
| Present Value of Terminal Value |
= Terminal Value ÷ (1 + r)5
= €603.64 ÷ (1 + 8.16%)5 |
€407.88 |
| Calculation | Result | |
|---|---|---|
| Total Equity Value |
= Present value of next 5 years cash flows +
Terminal Value
= €151.72 + €407.88 |
€559.61 |
| Equity Value per Share (EUR) |
= Total value / Shares Outstanding
= €559.61 / 14.95 |
€37.43 |
| Calculation | Result | |
|---|---|---|
| Value per share (EUR) | From above. | €37.43 |
| Current discount | Discount to share price of
€61.50
= -1 x (€61.50 - €37.43) / €37.43 |
-64.3% |
Learn more about our DCF calculations in Simply Wall St’s analysis model .
- The current share price of Pharmagest Interactive is above its future cash flow value.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for
it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing
when they are out of season, or how much your home is worth.The amount the stock market is willing to pay for Pharmagest Interactive's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are
Pharmagest Interactive's earnings available for a low price, and how does
this compare to other companies in the same industry?
| Data Point | Source | Value |
|---|---|---|
| Earnings Per Share * | Company Filings (2017-12-31) in EUR | €1.55 |
| ENXTPA:PHA Share Price ** | ENXTPA (2018-09-21) in EUR | €61.5 |
| Europe Healthcare Services Industry PE Ratio | Median Figure of 19 Publicly-Listed Healthcare Services Companies | 32.33x |
| France Market PE Ratio | Median Figure of 396 Publicly-Listed Companies | 17.04x |
* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.
** Primary Listing of Pharmagest Interactive.
| Calculation | Outcome | |
|---|---|---|
| PE Ratio | = ENXTPA:PHA Share Price ÷ EPS (both in EUR) = 61.5 ÷ 1.55 |
39.74x |
Learn more about our ratios and growth rates in Simply Wall St’s analysis model >
- Pharmagest Interactive is overvalued based on earnings compared to the Europe Healthcare Services industry average.
- Pharmagest Interactive is overvalued based on earnings compared to the France market.
Price based on expected Growth
Does
Pharmagest Interactive's expected growth come at a high price?
| Data Point | Source | Value |
|---|---|---|
| PE Ratio | See PE Ratio Section | 39.74x |
| Net Income Annual Growth Rate | See Future Growth Section. Line of Best Fit* through Consensus Estimate Earnings of 3 Analysts |
15.5%per year |
| Europe Healthcare Services Industry PEG Ratio | Median Figure of 12 Publicly-Listed Healthcare Services Companies | 2.28x |
| France Market PEG Ratio | Median Figure of 257 Publicly-Listed Companies | 1.7x |
*Line of best fit is calculated by linear regression .
| Calculation | Outcome | |
|---|---|---|
| PEG Ratio | = PE Ratio ÷ Net Income Annual Growth Rate = 39.74x ÷ 15.5% |
2.56x |
Learn more about our ratios and growth rates in Simply Wall St’s analysis model >
- Pharmagest Interactive is poor value based on expected growth next year.
Price based on value of assets
What value do investors place on
Pharmagest Interactive's
assets?
| Data Point | Source | Value |
|---|---|---|
| Book Value per Share | Company Filings (2017-12-31) in EUR | €7.58 |
| ENXTPA:PHA Share Price * | ENXTPA (2018-09-21) in EUR | €61.5 |
| France Healthcare Services Industry PB Ratio | Median Figure of 8 Publicly-Listed Healthcare Services Companies | 2.33x |
| France Market PB Ratio | Median Figure of 589 Publicly-Listed Companies | 1.67x |
| Calculation | Outcome | |
|---|---|---|
| PB Ratio | = ENXTPA:PHA Share Price ÷ Book Value per Share (both in EUR) = 61.5 ÷ 7.58 |
8.12x |
* Primary Listing of Pharmagest Interactive.
Learn more about our ratios and growth rates in Simply Wall St’s analysis model >
- Pharmagest Interactive is overvalued based on assets compared to the FR Healthcare Services industry average.
Value checks
We assess Pharmagest Interactive's value by looking at:- Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
- Is the PE ratio less than the market average, and/ or less than the Healthcare Services industry average (and greater than 0)? (2 checks)
- Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
- Is the PB ratio less than the Healthcare Services industry average (and greater than 0)? (1 check) Pharmagest Interactive has a total score of 0/6, see the detailed checks below.
Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.
Full details on the Value part of the Simply Wall St company analysis model.
PHA Future Performance
The future performance of a company is measured in the same way as past
performance, by looking at estimated
growth
and how much profit it is expected to make.Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Earnings growth vs Low Risk Savings
- Pharmagest Interactive's earnings growth is expected to exceed the low risk savings rate of 0.8%.
Growth vs Market Checks
- Pharmagest Interactive's earnings growth is expected to exceed the France market average.
- Pharmagest Interactive's revenue growth is expected to exceed the France market average.
Annual Growth Rates Comparison
| Data Point | Source | Value (per year) |
|---|---|---|
| ENXTPA:PHA Future Earnings Growth Rate | Line of Best Fit* through Consensus Estimate Earnings of 3 Analysts | 15.5% |
| ENXTPA:PHA Future Revenue Growth Rate | Line of Best Fit* through Consensus Estimate Revenue of 3 Analysts | 10.1% |
| France Healthcare Services Industry Earnings Growth Rate | Market Cap Weighted Average | 25.9% |
| France Healthcare Services Industry Revenue Growth Rate | Market Cap Weighted Average | 11.1% |
| France Market Earnings Growth Rate | Market Cap Weighted Average | 10.8% |
| France Market Revenue Growth Rate | Market Cap Weighted Average | 4.5% |
*Line of best fit is calculated by linear regression .
Industry and Market average data is calculated daily.
Learn more about our growth rate calculations in Simply Wall St’s analysis model.
Analysts growth expectations
| Data Point | Source | Value |
|---|---|---|
| Past Financials | Company Filings (8 months ago) | See Below |
| Future Estimates | Average of up to 3 Analyst Estimates (S&P Global) | See Below |
| Date (Data in EUR Millions) | Revenue | Cash Flow | Net Income * | Avg. No. Analysts |
|---|---|---|---|---|
| 2022-12-31 | 243 | 1 | ||
| 2021-12-31 | 217 | 1 | ||
| 2020-12-31 | 177 | 45 | 37 | 3 |
| 2019-12-31 | 162 | 38 | 31 | 3 |
| 2018-12-31 | 147 | 34 | 27 | 2 |
| Date (Data in EUR Millions) | Revenue | Cash Flow | Net Income * |
|---|---|---|---|
| 2017-12-31 | 147 | 27 | 23 |
| 2017-09-30 | 142 | 26 | 22 |
| 2017-06-30 | 137 | 25 | 21 |
| 2017-03-31 | 133 | 24 | 21 |
| 2016-12-31 | 128 | 23 | 21 |
| 2016-09-30 | 125 | 22 | 20 |
| 2016-06-30 | 121 | 22 | 20 |
| 2016-03-31 | 117 | 21 | 19 |
| 2015-12-31 | 113 | 20 | 19 |
| 2015-09-30 | 113 | 20 | 18 |
| 2015-06-30 | 112 | 21 | 18 |
| 2015-03-31 | 113 | 19 | 17 |
*GAAP earnings excluding extraordinary items.
Past and Future Earnings per Share
| Data Point | Source | Value |
|---|---|---|
| Past Financials | Company Filings (8 months ago) | See Below |
| Future Estimates | Average of up to 3 Analyst Estimates (S&P Global) | See Below |
All data from Pharmagest Interactive Company Filings, last reported 8 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.
| Date (Data in EUR Millions) | EPS * | EPS High Estimate | EPS Low Estimate | Avg. No. Analysts |
|---|---|---|---|---|
| 2022-12-31 | ||||
| 2021-12-31 | ||||
| 2020-12-31 | 2.37 | 2.55 | 2.12 | 3.00 |
| 2019-12-31 | 2.01 | 2.18 | 1.81 | 3.00 |
| 2018-12-31 | 1.71 | 1.78 | 1.65 | 2.00 |
| Date (Data in EUR Millions) | EPS * |
|---|---|
| 2017-12-31 | 1.55 |
| 2017-09-30 | 1.48 |
| 2017-06-30 | 1.41 |
| 2017-03-31 | 1.39 |
| 2016-12-31 | 1.37 |
| 2016-09-30 | 1.34 |
| 2016-06-30 | 1.31 |
| 2016-03-31 | 1.28 |
| 2015-12-31 | 1.25 |
| 2015-09-30 | 1.22 |
| 2015-06-30 | 1.18 |
| 2015-03-31 | 1.16 |
*GAAP earnings excluding extraordinary items.
Performance in 3 years
In the same way as past performance we look at the future estimated return
(profit) compared to the available
funds. We do this looking forward 3 years.
- Pharmagest Interactive is expected to efficiently use shareholders’ funds in the future (Return on Equity greater than 20%).
Future performance checks
We assess Pharmagest Interactive's future performance by looking at:- Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
- Is the annual earnings growth rate expected to beat the average growth rate in earnings of the France market? (1 check)
- Is the annual revenue growth rate expected to beat the average growth rate in revenue of the France market? (1 check)
- Is the annual earnings growth rate expected to be above 20%? (1 check)
- Is the annual revenue growth rate expected to be above 20%? (1 check)
- Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Pharmagest Interactive has a total score of 4/6, see the detailed checks below.
Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.
Full details on the Future part of the Simply Wall St company analysis model.
PHA Past Performance
How has Pharmagest Interactive performed over the past 5 years?
The past performance of a company can be measured by how much
growth
it has experienced and how much profit it makes relative to the funds and assets
it has available.
Past earnings growth
Past Earnings growth analysis
- Pharmagest Interactive's year on year earnings growth rate has been positive over the past 5 years.
- Pharmagest Interactive's 1-year earnings growth exceeds its 5-year average (12.5% vs 9.6%)
- Pharmagest Interactive's earnings growth has exceeded the Europe Healthcare Services industry average in the past year (12.5% vs 4.9%).
Earnings and Revenue History
All data from Pharmagest Interactive Company Filings, last reported 8 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.
| Date (Data in EUR Millions) | Revenue | Net Income * | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 2017-12-31 | 146.81 | 23.14 | ||
| 2017-09-30 | 141.84 | 22.12 | ||
| 2017-06-30 | 136.88 | 21.11 | ||
| 2017-03-31 | 132.63 | 20.84 | ||
| 2016-12-31 | 128.38 | 20.57 | ||
| 2016-09-30 | 124.60 | 20.06 | ||
| 2016-06-30 | 120.82 | 19.54 | ||
| 2016-03-31 | 117.15 | 19.17 | ||
| 2015-12-31 | 113.48 | 18.79 | ||
| 2015-09-30 | 112.96 | 18.17 | ||
| 2015-06-30 | 112.44 | 17.55 | ||
| 2015-03-31 | 113.50 | 17.28 | ||
| 2014-12-31 | 114.56 | 17.01 | ||
| 2014-09-30 | 113.57 | 16.75 | ||
| 2014-06-30 | 112.58 | 16.50 | ||
| 2014-03-31 | 112.99 | 16.16 | ||
| 2013-12-31 | 113.41 | 15.83 | ||
| 2013-09-30 | 113.12 | 15.19 | ||
| 2013-06-30 | 112.83 | 14.56 | ||
| 2013-03-31 | 110.78 | 14.04 | ||
| 2012-12-31 | 108.72 | 13.52 | ||
| 2012-09-30 | 105.29 | 13.13 | ||
| 2012-06-30 | 101.87 | 12.74 | ||
| 2012-03-31 | 99.47 | 12.25 | ||
| 2011-12-31 | 97.06 | 11.75 | ||
| 2011-09-30 | 96.20 | 11.48 |
*GAAP earnings excluding extraordinary items.
Performance last year
We want to ensure a company is making the most of what it has available. This is
done by comparing the return (profit) to a company's available
funds,
assets
and
capital.
- Pharmagest Interactive has efficiently used shareholders’ funds last year (Return on Equity greater than 20%).
- Pharmagest Interactive used its assets more efficiently than the Europe Healthcare Services industry average last year based on Return on Assets.
- Pharmagest Interactive's use of capital has not improved over the past 3 years (Return on Capital Employed).
Past performance checks
We assess Pharmagest Interactive's performance over the past 5 years by checking for:- Has earnings increased in past 5 years? (1 check)
- Has the earnings growth in the last year exceeded that of the Healthcare Services industry? (1 check)
- Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
- Is the Return on Equity (ROE) higher than 20%? (1 check)
- Is the Return on Assets (ROA) above industry average? (1 check)
- Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
Pharmagest Interactive has a total score of 5/6, see the detailed checks below.
Note: We use GAAP Net Income excluding extraordinary items in all our calculations.
Full details on the Past part of the Simply Wall St company analysis model.
PHA Health
How is Pharmagest Interactive's financial health and their level of debt?
A company's financial position is much like your own financial position,
it includes everything you own
(assets)
and owe
(liabilities).The boxes below represent the relative size of what makes up Pharmagest Interactive's finances.
The net worth of a company is the difference between its assets and liabilities.
- Pharmagest Interactive is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
- Pharmagest Interactive's cash and other short term assets cover its long term commitments.
Balance sheet
Assets
Liabilities and shares
- Low level of unsold assets.
- Debt is covered by short term assets, assets are 5.3x debt.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t
bad,
however if the debt is too high, or the company can’t afford to pay the interest
on its debts this may have impacts in the future.The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.
If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
All data from Pharmagest Interactive Company Filings, last reported 8 months ago.
| Date (Data in EUR Millions) | Total Equity | Total Debt | Cash & Short Term Investments |
|---|---|---|---|
| 2017-12-31 | 115.83 | 16.88 | 55.71 |
| 2017-09-30 | 115.83 | 16.88 | 55.71 |
| 2017-06-30 | 103.35 | 15.71 | 61.48 |
| 2017-03-31 | 103.35 | 15.71 | 61.48 |
| 2016-12-31 | 103.65 | 10.40 | 55.16 |
| 2016-09-30 | 103.65 | 10.40 | 55.16 |
| 2016-06-30 | 92.77 | 4.96 | 62.25 |
| 2016-03-31 | 92.77 | 4.96 | 62.25 |
| 2015-12-31 | 91.56 | 1.58 | 55.13 |
| 2015-09-30 | 91.56 | 1.58 | 55.13 |
| 2015-06-30 | 82.13 | 1.49 | 52.67 |
| 2015-03-31 | 82.13 | 1.49 | 52.67 |
| 2014-12-31 | 81.70 | 1.58 | 47.71 |
| 2014-09-30 | 81.70 | 1.58 | 47.71 |
| 2014-06-30 | 77.00 | 1.46 | 47.15 |
| 2014-03-31 | 77.00 | 1.46 | 47.15 |
| 2013-12-31 | 76.07 | 2.48 | 45.50 |
| 2013-09-30 | 76.07 | 2.48 | 45.50 |
| 2013-06-30 | 68.62 | 6.51 | 40.40 |
| 2013-03-31 | 68.62 | 6.51 | 40.40 |
| 2012-12-31 | 66.92 | 3.35 | 41.70 |
| 2012-09-30 | 66.92 | 3.35 | 41.70 |
| 2012-06-30 | 60.30 | 4.13 | 35.88 |
| 2012-03-31 | 60.30 | 4.13 | 35.88 |
| 2011-12-31 | 58.51 | 4.84 | 31.63 |
| 2011-09-30 | 58.51 | 4.84 | 31.63 |
- Pharmagest Interactive's level of debt (14.6%) compared to net worth is satisfactory (less than 40%).
- The level of debt compared to net worth has increased over the past 5 years (5.1% vs 14.6% today).
- Debt is well covered by operating cash flow (162.8%, greater than 20% of total debt).
- Pharmagest Interactive earns more interest than it pays, coverage of interest payments is not a concern.
Financial health checks
We assess Pharmagest Interactive's financial health by checking for:- Are short term assets greater than short term liabilities? (1 check)
- Are short term assets greater than long term liabilities? (1 check)
- Has the debt to equity ratio increased in the past 5 years? (1 check)
- Is the debt to equity ratio over 40%? (1 check)
- Is the debt covered by operating cash flow? (1 check)
- Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check) Pharmagest Interactive has a total score of 5/6, see the detailed checks below.
- Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
- Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
Full details on the Health part of the Simply Wall St company analysis model.
PHA Dividends
What is Pharmagest Interactive's current dividend yield, its reliability and sustainability?
Dividends are regular cash payments to you from the company, similar to a
bank paying you interest on a savings account.
Annual Dividend Income
If you bought
€2,000 of
Pharmagest Interactive
shares you are expected to receive
€24
in your first year as a dividend.
Dividend Amount
- Pharmagest Interactive's pays a lower dividend yield than the bottom 25% of dividend payers in France (1.44%).
- Pharmagest Interactive's dividend is below the markets top 25% of dividend payers in France (3.76%).
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not
wildly increasing/decreasing each year. This graph shows you the historical rate
to count toward your assessment of the stock.We also check to see if the dividend has increased in the past 10 years.
| Data Point | Source | Value |
|---|---|---|
| Past Annualized Dividend Yield | S&P Global Market Data | See Below |
| Past Dividends per Share | Company Filings/ Annualized Dividend Payments | See Below |
| Future Dividends per Share Estimates | Average of up to 3 Analyst Estimates (S&P Global) | See Below |
| Europe Healthcare Services Industry Average Dividend Yield | Market Cap Weighted Average of 10 Stocks | 1.4% |
| France Market Average Dividend Yield | Market Cap Weighted Average of 317 Stocks | 2.8% |
| France Minimum Threshold Dividend Yield | 10th Percentile | 0.9% |
| France Bottom 25% Dividend Yield | 25th Percentile | 1.4% |
| France Top 25% Dividend Yield | 75th Percentile | 3.8% |
Industry and Market average data is calculated daily.
Note all dividend per share amounts are annualized and not quarterly or other period.
| Date (Data in €) | Dividend per Share (annual) | Avg. No. Analysts |
|---|---|---|
| 2022-12-31 | ||
| 2021-12-31 | ||
| 2020-12-31 | 1.06 | 3.00 |
| 2019-12-31 | 0.92 | 3.00 |
| 2018-12-31 | 0.78 | 2.00 |
| Date (Data in €) | Dividend per share (annual) | Avg. Yield (%) |
|---|---|---|
| 2018-04-03 | 0.750 | 1.280 |
| 2017-04-28 | 0.650 | 1.452 |
| 2016-05-02 | 0.600 | 1.986 |
| 2015-04-30 | 0.580 | 2.563 |
| 2014-07-03 | 0.500 | 2.407 |
| 2013-04-26 | 0.420 | 2.413 |
| 2013-03-26 | 0.420 | 2.954 |
| 2012-04-26 | 0.360 | 3.332 |
| 2012-03-26 | 0.360 | 3.892 |
| 2011-04-28 | 0.300 | 3.339 |
| 2011-01-17 | 0.300 | 3.211 |
| 2010-04-28 | 0.280 | 3.171 |
| 2010-03-29 | 0.280 | 3.249 |
| 2009-04-28 | 0.270 | 3.306 |
| 2008-09-23 | 0.260 | 3.458 |
Learn more about our ratios and growth rates in Simply Wall St’s analysis model >
- Dividends per share have been stable in the past 10 years.
- Dividends per share have increased over the past 10 years.
Current Payout to shareholders
What portion of
Pharmagest Interactive's earnings are
paid
to the shareholders as a dividend.
- Dividends paid are well covered by earnings (2.1x coverage).
- Dividends after 3 years are expected to be well covered by earnings (2.2x coverage).
Income/ dividend checks
We assess Pharmagest Interactive's dividend by checking for:- Firstly is the company paying a notable dividend (greater than 0.9%) - if not then the rest of the checks are ignored.
- Is current dividend yield above the bottom 25% of dividend payers? (1 check)
- Is current dividend yield above the top 25% of dividend payers? (1 check)
- Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
- If they have paid a dividend for 10 years has it increased in this time? (1 check)
- How sustainable is the dividend, can Pharmagest Interactive afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks) Pharmagest Interactive has a total score of 4/6, see the detailed checks below.
Full details on the Dividends part of the Simply Wall St company analysis model.
PHA Management
CEO
| COMPENSATION | €229,462 |
| AGE | 53 |
CEO Bio
Mr. Dominique Pautrat serves as the Chief Executive Officer, Managing Director and Director of Pharmagest Interactive Societe Anonyme.
CEO Compensation
- Dominique's compensation has been consistent with company performance over the past year.
Management Team
Thierry Chapusot
Founder & Chairman of the Board
€24K
59
Dominique Pautrat
CEO, MD & Director
€229K
53
Thierry Ponnelle
Director of Marketing & Commercial Strategy
€135K
58
Denis Supplisson
Director of Solutions for Pharmacy Division - Europe
€183K
49
Jean-Yves Samson
Chief Administration & Financial Officer
Rodolphe Zimmer
Human Resources Director
Liza Natan
Director of E-Laboratories Division
Thierry Poivey
Director of Pharmacy Division - Belgium and Luxembourg
Grégory Rousseau
Research & Development Technical Director
Yannis Nahal
Director of E-Santé Solutions Division
Board of Directors
Dominique Pautrat
CEO, MD & Director
€229K
53
Thierry Ponnelle
Director of Marketing & Commercial Strategy
€135K
58
Denis Supplisson
Director of Solutions for Pharmacy Division - Europe
€183K
49
Marie-Louise Liger
Independent Director
€15K
66
3.3 yrs
Thierry Chapusot
Founder & Chairman of the Board
€24K
59
8.7 yrs
Daniel Antoine
Director
€5K
66
Hugues Moreaux
Director
65
François Jacquel
Director
€6K
60
Anne Lhote
Director
50
Sophie Mayeux
Independent Director
€750
61
Who owns this company?
Management checks
We assess Pharmagest Interactive's management by checking for:- Is the CEO's compensation unreasonable compared to market cap and profit (greater than 0.5% of the company's profit + 0.03% of market cap)? (1 check)
- Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
- Is the average tenure of the management team less than 2 years? (1 check)
- Is the average tenure of the board of directors team less than 3 years? (1 check) Pharmagest Interactive has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.
Note: We use the top 6 management executives and board members in our calculations.
Note 2: Insider trading include any internal stakeholders and these transactions .
Full details on the Management part of the Simply Wall St company analysis model.
PHA News
External News
Simply Wall St News
Analysts Bullish On Pharmagest Interactive SA (EPA:PHA)
Pharmagest Interactive SA (EPA:PHA) continues to post impressive revenue growth and its prospects have never been brighter. … I will conduct a high level fundamental analysis on the company by looking at its past financials and growth prospects moving forward. … Since starting in 1996 in France, the company has now grown to a market cap of €941.78m.
Simply Wall St - – Full articlePharmagest Interactive SA (EPA:PHA): Is Healthcare Attractive?
which continues to be affected by the sustained economic uncertainty and structural trends, such as an aging population, impacting the sector globally … Healthcare tech is facing a structural shift in terms of technology-enabled devices, which can progress innovation clinically and cost-effectively … Growth will be driven from advancements from robotic surgery, 3D printing, implantable devices and treatment, aimed at improving outcomes and reducing costs
Simply Wall St - – Full articlePharmagest Interactive SA (EPA:PHA): Why Return On Capital Employed Is Important
and looking to gauge the potential return on investment in Pharmagest Interactive SA (EPA:PHA). … Your return is tied to PHA’s ability to do this because the amount earned is used to invest in opportunities to grow the business or payout dividends, which are the two sources of return on investment. … Thus, to understand how your money can grow by investing in Pharmagest Interactive, you need to look at what the company returns to owners for the use of their capital, which can be done in many ways but today we will use return on capital employed (ROCE)
Simply Wall St - – Full articleDoes Pharmagest Interactive SA's (EPA:PHA) 12.49% Earnings Growth Reflect The Long-Term Trend?
Assessing Pharmagest Interactive SA's (EPA:PHA) performance as a company requires looking at more than just a years' earnings data. … Below, I will run you through a simple sense check to build perspective on how Pharmagest Interactive is doing by comparing its most recent earnings with its historical trend, in addition to the performance of its healthcare services industry peers. … PHA's trailing twelve-month earnings (from 31 December 2017) of €23.14m has
Simply Wall St - – Full articleIs Pharmagest Interactive SA (EPA:PHA) A Sell At Its Current PE Ratio?
and want to better understand how you can grow your money by investing in Pharmagest Interactive SA (EPA:PHA). … Pharmagest Interactive SA (EPA:PHA) is currently trading at a trailing P/E of 38x, which is higher than the industry average of 37.5x. … While PHA might seem like a stock to avoid or sell if you own it, it is important to understand the assumptions behind the P/E ratio before you make any investment decisions
Simply Wall St - – Full articlePharmagest Interactive SA (EPA:PHA): A Fundamentally Attractive Investment
Pharmagest Interactive SA (EPA:PHA) is a stock with outstanding fundamental characteristics. … When we build an investment case, we need to look at the stock with a holistic perspective. … In the case of PHA, it
Simply Wall St - – Full articlePharmagest Interactive SA (ENXTPA:PHA): What The Forecasts Are Telling Us
With analysts projecting … Pharmagest Interactive SA (ENXTPA:PHA) to … earnings growth of 15.41%
Simply Wall St - – Full articleIs Pharmagest Interactive SA's (EPA:PHA) Balance Sheet Strong Enough To Weather A Storm?
PHA has built up its total debt levels in the last twelve months, from €10.40M to €16.88M – this includes both the current and long-term debt. … Additionally, PHA has generated €27.48M in operating cash flow during the same period of time, resulting in an operating cash to total debt ratio of 162.80%, indicating that PHA’s debt is appropriately covered by operating cash. … Next Steps: PHA’s high cash coverage and low debt levels indicate its ability to utilise its borrowings efficiently in order to generate ample cash flow.
Simply Wall St - – Full articleBrokers' Outlook On Pharmagest Interactive SA (EPA:PHA)
ENXTPA:PHA Future Profit May 15th 18 The company is growing incredibly fast, with a year-on-year revenue growth of 14.35% over the past financial year , and a bottom line growth of 12.49%. … ENXTPA:PHA Historical Debt May 15th 18 Investors tend to get swept up by a company's growth prospects and promises, but a key element to always look at is its financial health in order to minimize the downside risk of investing. … Furthermore, PHA's debt level is at an appropriate 14.57% of equity, though it has been increasing over the past five years from 5.06%.
Simply Wall St - – Full articlePHA Company Info
Map
Description
Pharmagest Interactive SA engages in the development and commercialization of IT solutions for pharmacies and the pharmaceutical industry in Europe. The company operates through four divisions: Pharmaceuticals Solutions Europe, Solutions for Health and Medico-Social Institutions, e-Health Solutions, and Fintech. It offers LGPI, a pharmacy business management software; a range of SABCO software for the pharmacies in Belgium; OFFICINE 2016 flagship software for the pharmacies in Luxembourg; and OFFIDOSE 2.0, a pharmacy business management software. The company also provides robotic solutions for pharmacies, as well as dispenses medicines at the point of sale. In addition, it offers TITAN software suite, which provides a complete circuit of drug in the elderly housing establishment and day care centers for elderly people; and connected, secure, patient-oriented solutions for healthcare professionals. Further, the company offers patient services comprising observational tracking software; application services through mobile phone; DO-Pill, a connected pillbox, which allows patients to gain comfort and never forget their treatment; and communicating services. Additionally, it provides leasing financing solutions for the tertiary sector; and Leasa, a full Web computing gateway, which acts as a hub for accessing the financial partners, as well as managing sales financing processes. Pharmagest Interactive SA also offers IT equipment and services for pharmacy wholesalers and distributors. The company was founded in 1996 and is headquartered in Villers-les-Nancy, France. Pharmagest Interactive SA is a subsidiary of Marque Verte Sante.
Details
| Name: | Pharmagest Interactive SA |
| PHA | |
| Exchange: | ENXTPA |
| Founded: | 1996 |
| €919,358,334 | |
| 14,948,916 | |
| Website: | http://www.pharmagest.com |
| Address: |
Pharmagest Interactive SA 5 allée de Saint-Cloud, Villers-les-Nancy, Lorraine, 54600, France |
Listings
| Exchange Symbol | Ticker Symbol | Security | Exchange | Country | Currency | Listed on | |
|---|---|---|---|---|---|---|---|
| ENXTPA | PHA | Ordinary Shares | Euronext Paris | FR | EUR | 23. Oct 2000 | |
| LSE | 0R9T | Ordinary Shares | London Stock Exchange | GB | EUR | 23. Oct 2000 | |
| BATS-CHIXE | PHAP | Ordinary Shares | BATS 'Chi-X Europe' | GB | EUR | 23. Oct 2000 | |
| ENXTPA | PHA | EUR0.20 | Euronext Paris | FR | EUR | 22. Sep 2018 |
Number of employees
Current staff
Industry
| Health Care Technology | |
| Healthcare |
Company Analysis and Financial Data Status
| Area | Date (UTC time) |
|---|---|
| Company Analysis updated: | 2018/09/22 18:10 |
| End of day share price update: | 2018/09/21 00:00 |
| Last estimates confirmation: | 2018/09/18 |
| Last earnings filing: | 2018/04/27 |
| Last earnings reported: | 2017/12/31 |
| Last annual earnings reported: | 2017/12/31 |
All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
